There is a synthetic lethal relationship between SMARCA4 and the PTEN tumor suppressor in prostate cancer, rendering PTEN-deficient cells sensitive to SMARCA4 inhibition [111]. Here, SMARCA4 is linked to Familial prostate cancer.